INC Research Holdings Inc. (NASDAQ: INCR) announced that it has priced its secondary offering in its most recent filing to the U.S. Securities and Exchange Commission (SEC). However, it did not announce the actual price. As we get closer to the expected offering date of August 17, we can expect that more details — including the price — will surface.
Source: Thinkstock
Based on current prices, the offering of 8 million shares is valued at roughly $353 million.
In the previous filing, no underwriters were mentioned but this was updated to include JPMorgan and Credit Suisse. It is worth noting that INC will not receive any proceeds from this offering. Instead they will go to the selling shareholders. The biggest stakes being sold are by Avista Capital Partners, affiliates of Teachers’ Private Capital, and Ontario Teacher’s Pension Plan (OTPP).
This is a global contract research organization (CRO), based on revenues, and is exclusively focused on Phase 1 to Phase 4 clinical development services for the biopharmaceutical and medical device industries.
The company provides its customers highly differentiated therapeutic alignment and expertise, with a particular strength in central nervous system (CNS), oncology and other complex diseases. INC delivers clinical development services in a complex environment and offers a proprietary, operational approach to clinical trials through its Trusted Process methodology.
ALSO READ: 6 Analyst Stock Picks Called to Rise 50% to 100%
Its service offerings focus on optimizing the development of, and therefore the commercial potential for, customers’ new biopharmaceutical compounds, enhancing returns on their research and development (R&D) investments and reducing their overhead by offering an attractive variable cost alternative to fixed-cost, in-house resources.
Over the past decade, INC has built its scale and capabilities to become a leading global provider of Phase 1 to Phase 4 clinical development services, with about 6,100 employees in over 50 countries as of June 30, 2015. The company’s broad global reach has enabled it to provide clinical development services in more than 100 countries.
In the filing the company detailed its finances as follows:
For the years ended December 31, 2013 and 2014, we had total net service revenue of $652.4 million and $809.7 million, respectively, net loss of $(41.5) million and $(23.5) million, respectively, Adjusted Net Income of $16.3 million and $44.6 million, respectively. … Net service revenue, Adjusted Net Income increased by 24.1%, 174.1%, respectively, and net loss decreased by 43.5% for the year ended December 31, 2014 from the year ended December 31, 2013. … Net service revenue, net income, Adjusted Net Income and Adjusted EBITDA increased by 13.0%, 253.2%, 216.9% and 53.4%, respectively, for the six months ended June 30, 2015 from the six months ended June 30, 2014.
Wednesday morning, shares of INC were down 8% to $44.33, within its post-IPO trading range of $19.61 to $51.69. The stock has a consensus analyst price target of $52.60.
ALSO READ: 4 High-Flying Stocks That Have Sold Off Far Too Much
Essential Tips for Investing: Sponsored
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
